Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Olanzapine Teva

Olanzapine Teva 5 mg orodispersible tablets Olanzapine Teva 10 mg orodispersible tablets Olanzapine Teva 15 mg orodispersible tablets Olanzapine Teva 20 mg orodispersible tablets · Abschnitt 4.8 · PDF-Seite 26–27

HOS-209101 · Präparat HOS-154237

26  Hypersensitivity11 Metabolism and nutrition disorders Weight gain1 Elevated Development or Hypothermia12 cholesterol exacerbation of levels2,3 diabetes Elevated glucose occasionally levels4 associated with Elevated ketoacidosis or triglyceride coma, including levels2,5 some fatal cases Glucosuria (see section 4.4)11 Increased appetite Nervous system disorders Somnolence Dizziness Seizures where in Neuroleptic Akathisia6 most cases a malignant Parkinsonism6 history of seizures syndrome (see Dyskinesia6 or risk factors for section 4.4)12 seizures were Discontinuation reported11 symptoms7,12 Dystonia (including oculogyration)11 Tardive dyskinesia11 Amnesia9 Dysarthria Stuttering11 Restless legs syndrome11 Cardiac disorders Bradycardia Ventricular QTc prolongation tachycardia/fibrill (see section 4.4) ation, sudden death (see section 4.4)11 Vascular disorders Orthostatic Thromboembolis hypotension10 m (including pulmonary embolism and deep vein thrombosis) (see section 4.4) Respiratory, thoracic and mediastinal disorders Epistaxis9 Gastrointestinal disorders Mild, transient Abdominal Pancreatitis11 anticholinergic distension9 effects including Salivary constipation and hypersecretion11 dry mouth Hepatobiliary disorders Transient, Hepatitis asymptomatic (including elevations of hepatocellular, hepatic cholestatic or

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.